Advertisement

Pharmaceutical Research

, Volume 31, Issue 4, pp 837–846 | Cite as

Current Challenges in Bioequivalence, Quality, and Novel Assessment Technologies for Topical Products

  • Avraham Yacobi
  • Vinod P. Shah
  • Edward D. Bashaw
  • Eva Benfeldt
  • Barbara Davit
  • Derek Ganes
  • Tapash Ghosh
  • Isadore Kanfer
  • Gerald B. Kasting
  • Lindsey Katz
  • Robert Lionberger
  • Guang Wei Lu
  • Howard I. Maibach
  • Lynn K. Pershing
  • Russell J. Rackley
  • Andre Raw
  • Chinmay G. Shukla
  • Kailas Thakker
  • Nathalie Wagner
  • Elizabeta Zovko
  • Majella E. Lane
Expert Review

Abstract

This paper summarises the proceedings of a recent workshop which brought together pharmaceutical scientists and dermatologists from academia, industry and regulatory agencies to discuss current regulatory issues and industry practices for establishing therapeutic bioequivalence (BE) of dermatologic topical products. The methods currently available for assessment of BE were reviewed as well as alternatives and the advantages and disadvantages of each method were considered. Guidance on quality and performance of topical products was reviewed and a framework to categorise existing and alternative methods for evaluation of BE was discussed. The outcome of the workshop emphasized both a need for greater attention to quality, possibly, via a Quality-By-Design (QBD) approach and a need to develop a “whole toolkit” approach towards the problem of determination of rate and extent in the assessment of topical bioavailability. The discussion on the BE and clinical equivalence of topical products revealed considerable concerns about the variability present in the current methodologies utilized by the industry and regulatory agencies. It was proposed that academicians, researchers, the pharmaceutical industry and regulators work together to evaluate and validate alternative methods that are based on both the underlying science and are adapted to the drug product itself instead of single “universal” method.

KEY WORDS

bioequivalence dermatologic topical product generic in vitro in vivo quality-by-design 

Notes

ACKNOWLEDGMENTS AND DISCLOSURES

The views expressed here are the views of the scientists and do not represent the policy of their respective agencies or organization.

The Product Quality Research Institute (PQRI) is a non-profit consortium of organizations working together to generate and share timely, relevant, and impactful information that advances drug product quality and development.

By virtue of its diverse membership, PQRI provides a unique forum to focus critical thinking, conduct research, exchange information, and propose methodology or guidance to pharmaceutical companies, regulators, and standard setting organizations.

REFERENCES

  1. 1.
    US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products—general considerations.2003.Google Scholar
  2. 2.
    Code of Federal Regulations. Title 21 Part 320 0.24 (b) (1–4)Google Scholar
  3. 3.
  4. 4.
    Abbreviated New Drug Application 202459.Google Scholar
  5. 5.
    Guidance: topical dermatologic corticosteroids: in vivo bioequivalence, Office of Generic Drugs, Center for Drug Evaluations and Research, FDA. 1995.Google Scholar
  6. 6.
    US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2000.Google Scholar
  7. 7.
    Generic Drug Savings in the US. Fourth Annual Edition. Generic Pharmaceutical Association. 2012.Google Scholar
  8. 8.
  9. 9.
  10. 10.
  11. 11.
    Abbreviated New Drug Application 200675.Google Scholar
  12. 12.
    McKenzie AW, Stoughton RB. Method of comparing percutaneous absorption of steroids. Arch Dermatol. 1962;86:608–10.CrossRefGoogle Scholar
  13. 13.
    US FDA. Guidance for Industry: Topical dermatological drug product NDAs and ANDAs-in vivo bioavailability, bioequivalence, in vitro release, and associated studies. Draft Guidance, June 1998, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. 1998.Google Scholar
  14. 14.
    US FDA. Guidance for industry on special protocol assessment; availability. Fed Regist. 2002;67:35122.Google Scholar
  15. 15.
    Pershing LK. Bioequivalence assessment of three 0.025% tretinoin gel products: Dermatopharmacokinetic vs. Clinical Trial Methods, Transcribed presentation to the Advisory Committee for Pharmaceutical Sciences Meeting. Rockville: Center for Drug Evaluation and Research, FDA; 2001.Google Scholar
  16. 16.
    Franz TJ. Study #1, Avita Gel 0.025% vs Retin-A Gel 0.025%, Transcribed presentation, Advisory Committee for Pharmaceutical Sciences Meeting. Rockville: Center for Drug Evaluation and Research, FDA; 2001.Google Scholar
  17. 17.
    Bunge AL, N’Dri-Stempfer B, Navidi WC, Guy RH. Dermatopharmacokinetics: improvement of methodology for assessing bioequivalence of topical dermatological drug products, Revised Final Report, Award No. D3921303, Submitted to Department of Health and Human Services. Golden: FDA, Colorado School of Mines; 2006.Google Scholar
  18. 18.
    Bunge AL, N’Dri-Stempfer B, Navidi WC, Guy RH. Therapeutic Equivalence of Topical Products, Final Report, Award No. 223-04-3004, Submitted to Department of Health and Human Services, FDA, Colorado School of Mines, Golden, CO, January 30, 2007 (Revision submitted June 2008).Google Scholar
  19. 19.
    Au WL, Skinner M, Kanfer I. Comparison of tape stripping with the human skin blanching assay for the bioequivalence assessment of topical clobetasol propionate formulation. J Pharm Pharmaceut Sci. 2010;13:11–20.Google Scholar
  20. 20.
    Parfitt NR, Skinner M, Bon C, Kanfer I. Bioequivalence of topical clotrimazole formulations: an improved tape stripping method. J Pharm Pharmaceut Sci. 2011;14:347–57.Google Scholar
  21. 21.
    Stoughton RB. Dimethylsulfoxide (DMSO) induction of a steroid reservoir in human skin. Arch Dermatol. 1965;91:657–60.PubMedCrossRefGoogle Scholar
  22. 22.
    Santos P, Watkinson AC, Hadgraft J, Lane ME. Oxybutynin permeation in skin: the influence of drug and solvent activity. Int J Pharm. 2010;384:67–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Ungerstedt U. Measurement of neurotransmitter release by intracranial dialysis. In: Marsden CA, editor. Measurement of neurotransmitter release in vivo. Chichester: Wiley; 1984. p. 81–105.Google Scholar
  24. 24.
    Petersen LJ, Kristensen JK, Bülow J. Microdialysis of the interstitial water space in human skin in vivo: quantitative measurement of cutaneous glucose concentrations. J Invest Dermatol. 1992;99:357–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Anderson C, Andersson T, Molander M. Ethanol absorption across human skin measured by in vivo microdialysis technique. Acta Derm Venereol. 1991;71:389–93.PubMedGoogle Scholar
  26. 26.
    Ortiz PG, Hansen SH, Shah VP, Menné T, Benfeldt E. The effect of irritant dermatitis on cutaneous bioavailability of a metronidazole formulation, investigated by microdialysis and dermatopharmacokinetic method. Contact Dermatitis. 2008;59:23–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Ortiz PG, Hansen SH, Shah VP, Menné T, Benfeldt E. Impact of adult atopic dermatitis on topical drug penetration: assessment by cutaneous microdialysis and tape stripping. Acta Derm Venereol. 2009;89:33–8.Google Scholar
  28. 28.
    Benfeldt E, Hansen SH, Vølund A, Menné T, Shah VP. Bioequivalence of topical formulations in humans: evaluation by dermal microdialysis sampling and the dermatopharmacokinetic method. J Invest Dermatol. 2007;127:170–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Tettey-Amlalo RN, Kanfer I, Skinner MF, Benfeldt E, Verbeeck RK. Application of dermal microdialysis for the evaluation of bioequivalence of a ketoprofen topical gel. Eur J Pharm Sci. 2009;36:219–25.PubMedCrossRefGoogle Scholar
  30. 30.
    Holmgaard R, Nielsen JB, Benfeldt E. Microdialysis sampling for investigations of bioavailability and bioequivalence of topically administered drugs: current state and future perspectives. Skin Pharmacol Physiol. 2010;23:225–43.PubMedCrossRefGoogle Scholar
  31. 31.
    Trajanoski Z, Brunner GA, Schaupp L, Ellmerer M, Wach P, Pieber TR, et al. Open-flow microperfusion of subcutaneous adipose tissue for on-line continuous ex vivo measurement of glucose concentration. Diabetes Care. 1997;20:1114–21.PubMedCrossRefGoogle Scholar
  32. 32.
    Bodenlenz M, Hoefferer C, Priedl J, Dragatin C, Korsatko S, Liebenberger L, et al. A novel certified dermal sampling system for efficient clinical research. J Invest Dermatol. 2011;131 Suppl 2:S44.Google Scholar
  33. 33.
    Bodenlenz M, Höfferer C, Magnes C, Schaller-Ammann R, Schaupp L, Feichtner F, et al. Dermal PK/PD of a lipophilic topical drug in psoriatic patients by continuous intradermal membrane-free sampling. Eur J Pharm Biopharm. 2012;81:635–41.PubMedCrossRefGoogle Scholar
  34. 34.
    Caspers PJ, Lucassen GW, Bruining HA, Puppels GJ. Automated depth-scanning confocal Raman microspectrometer for rapid in vivo determination of water concentration profiles in human skin. J Raman Spectrosc. 2000;31:813–8.CrossRefGoogle Scholar
  35. 35.
    Crowther JM, Sieg A, Blenkiron P, Marcott C, Matts PJ, Kaczvinsky JR, et al. Measuring the effects of topical moisturizers on changes in stratum corneum thickness, water gradients and hydration in vivo. Br J Dermatol. 2008;159:567–77.PubMedGoogle Scholar
  36. 36.
    Caspers PJ, Lucassen GW, Carter EA, Bruining HA, Puppels GJ. In vivo confocal Raman microspectroscopy of the skin: noninvasive determination of molecular concentration profiles. J Invest Dermatol. 2001;116:434–42.PubMedCrossRefGoogle Scholar
  37. 37.
    Mohammed D, Crowther JM, Matts PJ, Hadgraft J, Lane ME. Influence of niacinamide containing formulations on the molecular and biophysical properties of the stratum corneum. Int J Pharm. 2013;441:192–201.PubMedCrossRefGoogle Scholar
  38. 38.
    Puppels GJ, Sterenborg HJCM. Laser safety aspects of the use of the Model 3510 Skin Composition Analyzer (SCA) in in vivo studies of human subjects. River Diagnostics. 2007. 23 pp.Google Scholar
  39. 39.
    Mateus R, Abdalghafor H, Oliveira G, Hadgraft J, Lane ME. A new paradigm in dermatopharmacokinetics - Confocal Raman spectroscopy. Int J Pharm. 2013;444:106–8.PubMedCrossRefGoogle Scholar
  40. 40.
    OECD (2004) Test No. 428: Skin Absorption: In vitro method. OECD 2004 8 pp.Google Scholar
  41. 41.
    Skelly JP, Sha VP, Maibach HI, Guy RH, Wester RC, Flynn G, et al. FDA and AAPS report of the workshop on principles and practices of in vitro percutaneous penetration studies: relevance to bioavailability and bioequivalence. Pharm Res. 1987;4:265–7.CrossRefGoogle Scholar
  42. 42.
    Franz TJ, Lehman PA, Raney SG. Use of excised human skin to assess the bioequivalence of topical products. Skin Pharmacol Physiol. 2009;22:276–86.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    FDA. SUPAC-SS nonsterile semisolid dosage forms, scale-up and postapproval changes: chemistry, manufacturing, and controls; in vitro release testing and in vivo bioequivalence documentation. U.S. Department of Health and Human Services, Washington,DC. 1997. http://www.fda.gov/cder/guidance/1447fnl.pdf(accessed 09 April 2007).
  44. 44.
    Chang R-K, Raw A, Lionberger Y. L. Generic development of topical dermatologic products: Formulation development, process development, and testing of topical dermatologic products. AAPS Journal. 2013;15:41–52.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Avraham Yacobi
    • 1
  • Vinod P. Shah
    • 2
  • Edward D. Bashaw
    • 3
  • Eva Benfeldt
    • 4
  • Barbara Davit
    • 3
  • Derek Ganes
    • 5
  • Tapash Ghosh
    • 3
  • Isadore Kanfer
    • 6
  • Gerald B. Kasting
    • 7
  • Lindsey Katz
    • 8
  • Robert Lionberger
    • 3
  • Guang Wei Lu
    • 9
  • Howard I. Maibach
    • 10
  • Lynn K. Pershing
    • 11
  • Russell J. Rackley
    • 12
  • Andre Raw
    • 3
  • Chinmay G. Shukla
    • 3
  • Kailas Thakker
    • 13
  • Nathalie Wagner
    • 14
  • Elizabeta Zovko
    • 15
  • Majella E. Lane
    • 16
  1. 1.DOLE Pharma LLCNew YorkUSA
  2. 2.Pharmaceutical ConsultantNorth PotomacUSA
  3. 3.U.S. Food and Drug AdministrationSilver SpringUSA
  4. 4.Department of DermatologyUniversity of Copenhagen Roskilde HospitalCopenhagenDenmark
  5. 5.Ganes Pharma Inc.TorontoCanada
  6. 6.Rhodes UniversityGrahamstownSouth Africa
  7. 7.University of CincinnatiCincinnatiUSA
  8. 8.Biostudy Solutions LLCWilmingtonUSA
  9. 9.AllerganIrvineUSA
  10. 10.University of California–San FranciscoSan FranciscoUSA
  11. 11.University of Utah Health Sciences CenterSalt Lake CityUSA
  12. 12.Mylan Pharmaceuticals IncMorgantownUSA
  13. 13.Tergus Pharma LLCDurhamUSA
  14. 14.Galderma R&DSophia AntipolisFrance
  15. 15.Forest Research InstituteNew YorkUSA
  16. 16.University College London School of PharmacyLondonUK

Personalised recommendations